WuXi NextCODE, a Shanghai, China- Cambridge, Massachusetts- and Reykjavik, Iceland-based provider of a global platform for genomic data, completed $240M a Series B financing.
The round was led by Sequoia China with participation from Temasek, Yunfeng Capital and 3W Partners.
The company intends to use the funds to accelerate the extension of its platform infrastructure and to bring new users and data onboard through precision medicine and diagnostics partnerships and the commercialization of its consumer solutions for the China market.
Led by Hannes Smarason, CEO, and Dr. Ge Li, chairman, WuXi NextCODE is a fully integrated contract genomics organization (CGO) building the global standard platform for genomic data serving population genomics, precision medicine, diagnostics and wellness initiatives and enterprises.
capabilities span study design, sequencing, secondary analysis, storage, interpretation, scalable analytics, and AI and deep learning – all backed by technology for organizing, mining and sharing genome sequence data. It is also applying the same capabilities to advance a growing range of sequence-based tests and scans in China.